204 related articles for article (PubMed ID: 33162805)
1.
Zhu X; Zhang Y; Bai Y; Gu X; Chen G; Sun L; Wang Y; Qiao X; Ma Q; Zhu T; Bu J; Xue J; Liu C
Int J Med Sci; 2020; 17(17):2773-2789. PubMed ID: 33162805
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive analysis of the expression, prognostic significance, and regulation pathway of G2E3 in breast cancer.
Shen Y; Xue J; Yu J; Jiang Y; Bu J; Zhu T; Gu X; Zhu X
World J Surg Oncol; 2022 Dec; 20(1):398. PubMed ID: 36517818
[TBL] [Abstract][Full Text] [Related]
3. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and Therapeutic Significance of Adhesion-regulating Molecule 1 in Estrogen Receptor-positive Breast Cancer.
Wu W; Zhong J; Chen J; Niu P; Ding Y; Han S; Xu J; Dai L
Clin Breast Cancer; 2020 Apr; 20(2):131-144.e3. PubMed ID: 31669266
[TBL] [Abstract][Full Text] [Related]
5. miRNA‑490‑3p promotes the metastatic progression of invasive ductal carcinoma.
Lu N; Zhang M; Lu L; Liu YZ; Zhang HH; Liu XD
Oncol Rep; 2021 Feb; 45(2):706-716. PubMed ID: 33416185
[TBL] [Abstract][Full Text] [Related]
6. A Systematic Literature Review of the Prognostic and Predictive Value of PIK3CA Mutations in HR
Mollon LE; Anderson EJ; Dean JL; Warholak TL; Aizer A; Platt EA; Tang DH; Davis LE
Clin Breast Cancer; 2020 Jun; 20(3):e232-e243. PubMed ID: 32234362
[TBL] [Abstract][Full Text] [Related]
7. Rac1 activation in human breast carcinoma as a prognostic factor associated with therapeutic resistance.
Yamaguchi M; Takagi K; Sato A; Miki Y; Miyashita M; Sasano H; Suzuki T
Breast Cancer; 2020 Sep; 27(5):919-928. PubMed ID: 32314182
[TBL] [Abstract][Full Text] [Related]
8. Pre-surgical level of von Willebrand factor as an evident indicator of breast cancer recurrence.
Rhone P; Zarychta E; Bielawski K; Ruszkowska-Ciastek B
Cancer Biomark; 2020; 29(3):359-372. PubMed ID: 32716345
[TBL] [Abstract][Full Text] [Related]
9. Association with pregnancy increases the risk of local recurrence but does not impact overall survival in breast cancer: A case-control study of 87 cases.
Genin AS; De Rycke Y; Stevens D; Donnadieu A; Langer A; Rouzier R; Lerebours F
Breast; 2016 Dec; 30():222-227. PubMed ID: 26456897
[TBL] [Abstract][Full Text] [Related]
10. Hsa_circ_001569 is an unfavorable prognostic factor and promotes cell proliferation and metastasis by modulating PI3K-AKT pathway in breast cancer.
Xu JH; Wang Y; Xu D
Cancer Biomark; 2019; 25(2):193-201. PubMed ID: 31104012
[TBL] [Abstract][Full Text] [Related]
11. GALNT6 promotes breast cancer metastasis by increasing mucin-type O-glycosylation of α2M.
Liu C; Li Z; Xu L; Shi Y; Zhang X; Shi S; Hou K; Fan Y; Li C; Wang X; Zhou L; Liu Y; Qu X; Che X
Aging (Albany NY); 2020 Jun; 12(12):11794-11811. PubMed ID: 32559179
[TBL] [Abstract][Full Text] [Related]
12. STEAP2 is down-regulated in breast cancer tissue and suppresses PI3K/AKT signaling and breast cancer cell invasion in vitro and in vivo.
Yang Q; Ji G; Li J
Cancer Biol Ther; 2020; 21(3):278-291. PubMed ID: 31696760
[TBL] [Abstract][Full Text] [Related]
13. PIK3R1 targeting by miR-21 suppresses tumor cell migration and invasion by reducing PI3K/AKT signaling and reversing EMT, and predicts clinical outcome of breast cancer.
Yan LX; Liu YH; Xiang JW; Wu QN; Xu LB; Luo XL; Zhu XL; Liu C; Xu FP; Luo DL; Mei P; Xu J; Zhang KP; Chen J
Int J Oncol; 2016 Feb; 48(2):471-84. PubMed ID: 26676464
[TBL] [Abstract][Full Text] [Related]
14. BRAF/MEK Pathway is Associated With Breast Cancer in ER-dependent Mode and Improves ER Status-based Cancer Recurrence Prediction.
Liu D; Zhou K
Clin Breast Cancer; 2020 Feb; 20(1):41-50.e8. PubMed ID: 31547956
[TBL] [Abstract][Full Text] [Related]
15. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2-Directed Chemotherapy in HER2-Positive Breast Cancer.
Meisel JL; Zhao J; Suo A; Zhang C; Wei Z; Taylor C; Aneja R; Krishnamurti U; Li Z; Nahta R; O'Regan R; Li X
Clin Breast Cancer; 2020 Feb; 20(1):19-24. PubMed ID: 31806448
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological Characteristics of
Lee MH; Cho JH; Kwon SY; Jung SJ; Lee JH
Int J Med Sci; 2020; 17(8):1131-1135. PubMed ID: 32410843
[TBL] [Abstract][Full Text] [Related]
18. HCK is a Potential Prognostic Biomarker that Correlates with Immune Cell Infiltration in Acute Myeloid Leukemia.
Cheng F; Li Q; Wang J; Wang L; Li W; Zeng F
Dis Markers; 2022; 2022():3199589. PubMed ID: 35280440
[TBL] [Abstract][Full Text] [Related]
19. Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer.
Hergueta-Redondo M; Sarrio D; Molina-Crespo Á; Vicario R; Bernadó-Morales C; Martínez L; Rojo-Sebastián A; Serra-Musach J; Mota A; Martínez-Ramírez Á; Castilla MÁ; González-Martin A; Pernas S; Cano A; Cortes J; Nuciforo PG; Peg V; Palacios J; Pujana MÁ; Arribas J; Moreno-Bueno G
Oncotarget; 2016 Aug; 7(35):56295-56308. PubMed ID: 27462779
[TBL] [Abstract][Full Text] [Related]
20. The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast.
Zhao H
Breast Cancer; 2021 Jan; 28(1):187-195. PubMed ID: 32812198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
